AR024462A1 - Tabletas farmaceuticas - Google Patents

Tabletas farmaceuticas

Info

Publication number
AR024462A1
AR024462A1 ARP000103154A ARP000103154A AR024462A1 AR 024462 A1 AR024462 A1 AR 024462A1 AR P000103154 A ARP000103154 A AR P000103154A AR P000103154 A ARP000103154 A AR P000103154A AR 024462 A1 AR024462 A1 AR 024462A1
Authority
AR
Argentina
Prior art keywords
tablets
pharmaceutical tablets
refers
pharmaceutical
bisphosphonates
Prior art date
Application number
ARP000103154A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR024462A1 publication Critical patent/AR024462A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a tabletas farmacéuticas, utiles para administrar ingredientes activos farmacéuticos, tales como bisfosfonatos. Estas tabletas hanmejorado las propiedades superficiales que pueden ayudar al tránsito esofageal, reduciendo así elpotencial de los efectos gastrointestinales adversos. Lapresente también se refiere a procesos para preparar dichas tabletas farmacéuticas nuevas.
ARP000103154A 1999-07-01 2000-06-23 Tabletas farmaceuticas AR024462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14198799P 1999-07-01 1999-07-01

Publications (1)

Publication Number Publication Date
AR024462A1 true AR024462A1 (es) 2002-10-02

Family

ID=22498098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103154A AR024462A1 (es) 1999-07-01 2000-06-23 Tabletas farmaceuticas

Country Status (11)

Country Link
US (2) US20010036475A1 (es)
EP (1) EP1196175A1 (es)
JP (1) JP2003503460A (es)
KR (1) KR20020015063A (es)
AR (1) AR024462A1 (es)
AU (1) AU6055400A (es)
CA (1) CA2378521A1 (es)
HK (1) HK1041816A1 (es)
IL (1) IL146632A0 (es)
NZ (1) NZ515614A (es)
WO (1) WO2001001991A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
NZ552514A (en) 2001-12-24 2008-08-29 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
CN1939314A (zh) 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
SI1596870T2 (sl) 2002-12-20 2011-07-29 Hoffmann La Roche Formulacija z visokim odmerkom ibandronata
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US9711456B2 (en) 2015-12-19 2017-07-18 International Business Machines Corporation Composite manganese nitride/low-K dielectric cap
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
WO2020156959A1 (de) * 2019-01-28 2020-08-06 Katjes Fassin Gmbh. + Co. Kommanditgesellschaft Apfelwachs-beinhaltende zusammensetzungen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1036368A (en) 1963-10-31 1966-07-20 Nat Dairy Prod Corp Method for the manufacture of lactose-containing tablets
DE2534391C2 (de) 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JPH07100665B2 (ja) 1987-12-23 1995-11-01 信越化学工業株式会社 被覆薬剤の製造方法
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE69730982T2 (de) * 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
ES2226128T3 (es) 1997-06-11 2005-03-16 THE PROCTER & GAMBLE COMPANY Comprimido revestido con una pelicula para una seguridad del tracto gastrointestinal superior mejorada.
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제

Also Published As

Publication number Publication date
WO2001001991A1 (en) 2001-01-11
US20010036475A1 (en) 2001-11-01
KR20020015063A (ko) 2002-02-27
US20020187186A1 (en) 2002-12-12
CA2378521A1 (en) 2001-01-11
IL146632A0 (en) 2002-07-25
EP1196175A1 (en) 2002-04-17
NZ515614A (en) 2004-01-30
AU6055400A (en) 2001-01-22
JP2003503460A (ja) 2003-01-28
HK1041816A1 (zh) 2002-07-26
US6623755B2 (en) 2003-09-23

Similar Documents

Publication Publication Date Title
AR024462A1 (es) Tabletas farmaceuticas
GT199900203A (es) Composiciones de celecoxib.
DOP2000000109A (es) Derivados de tiazolilamida
AR023401A1 (es) Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con restos de azucar, procedimientos para su preparacion, medicamentos que contienen estoscompuestos, y su empleo para preparar un medicamento
BRPI0509184A (pt) composições farmacêuticas
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
AR053412A1 (es) Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CO6362017A2 (es) Peptidos antivirales terapeuticos
CO5390076A1 (es) Composiciones farmaceuticas
CO5590918A2 (es) Formulaciones
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
AR026338A1 (es) Dihidrotiazoles policiclicos, provistos en posicion 2 de radicales alquilo sustituidos, procedimiento para su preparacion y su utilizacion comomedicamentos
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
AR003434A1 (es) Compuesto de tiludronato, composiciones farmaceuticas que los contienen y proceso para producir dicho compuesto y procedimiento para producir lascomposiciones farmaceuticas.
BRPI0509067A (pt) formulações de matriz oral que compreendem licarbazepina
AR026451A1 (es) Compuestos heterociclicos sililados
UY26250A1 (es) Sulfonamidas sustituidas con naftilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal